Tradfi
Sectors
Sentiment
Bitcoin vs Pfizer — digital scarce asset vs big-pharma company navigating post-COVID revenue cliff.
| Metric | Bitcoin | Pfizer | Δ |
|---|---|---|---|
| Bitcoin Market Cap | $1.56T | — | — |
| Bitcoin Price | $77.66K | — | — |
| Bitcoin 24h Change | -0.20% | — | — |
| Bitcoin FDV | $1.56T | — | +0.0% |
| Bitcoin ATH | $126.08K | — | — |
Crypto data live from Sharpe's tracker cache; TradFi values are reference benchmarks updated quarterly.
Pfizer's market cap has ranged $140B-$200B in 2024-2026, down materially from its 2021-2022 peak (~$330B) after COVID-19 vaccine revenue rolled off. Bitcoin's market cap ($1T-$2.5T) is 5-18x Pfizer. Pfizer's revenue declined from $100B+ in 2022 to $60B in 2024 as COVID-related products normalized — an object lesson in 'temporary-catalyst' valuation. Bitcoin has no such catalyst cliff since it has no underlying revenue. For allocators thinking about valuation durability, the Pfizer comparison is instructive: revenue-cliff risk is a specific tradable-equity vulnerability BTC does not share. Correlation near zero.
Side-by-side crypto comparison with normalized returns
Rolling correlation between crypto and major TradFi benchmarks